NASDAQ · ALC
Healthcare · Medical - Instruments & Supplies
$64.11
Up+$0.98 (+1.55%)
Updated Oct 10, 2026, 9:59 PM
SID Score
5.2/10
Composite research score
Smart Money
51/100
Neutral
Price performance · ALC
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
ALC closed at $64.11 after 21 trading sessions, down 2.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $63.87 | $64.195 | $63.53 | $64.11 | 1.35M |
| Oct 8, 2026 | $62.49 | $63.295 | $62.43 | $63.13 | 1.19M |
| Oct 7, 2026 | $63.36 | $63.685 | $62.94 | $63.00 | 1.54M |
| Oct 6, 2026 | $64.16 | $64.19 | $62.99 | $63.19 | 2.39M |
| Oct 5, 2026 | $63.65 | $64.35 | $63.55 | $64.33 | 1.38M |
| Oct 2, 2026 | $64.39 | $64.42 | $63.50 | $63.76 | 1.27M |
| Oct 1, 2026 | $64.64 | $64.82 | $63.40 | $63.94 | 2.22M |
| Sep 30, 2026 | $65.26 | $65.28 | $64.51 | $64.75 | 1.6M |
| Sep 29, 2026 | $65.50 | $65.52 | $64.7334 | $65.44 | 2.29M |
| Sep 28, 2026 | $65.01 | $65.445 | $64.36 | $65.26 | 2.32M |
| Sep 25, 2026 | $64.02 | $64.70 | $64.02 | $64.47 | 2.46M |
| Sep 24, 2026 | $65.07 | $65.38 | $64.24 | $64.56 | 1.74M |
| Sep 23, 2026 | $65.15 | $65.71 | $65.06 | $65.39 | 1.05M |
| Sep 22, 2026 | $65.40 | $65.745 | $64.98 | $65.59 | 947.69K |
| Sep 21, 2026 | $65.825 | $65.825 | $64.85 | $64.87 | 1.32M |
| Sep 18, 2026 | $64.75 | $65.60 | $64.54 | $65.04 | 3.46M |
| Sep 17, 2026 | $66.27 | $66.275 | $64.70 | $65.18 | 2.14M |
| Sep 16, 2026 | $67.19 | $67.55 | $66.125 | $66.30 | 1.71M |
| Sep 15, 2026 | $67.06 | $67.935 | $66.95 | $67.76 | 1.51M |
| Sep 14, 2026 | $67.31 | $67.79 | $66.64 | $67.74 | 1.87M |
| Sep 11, 2026 | $67.26 | $67.415 | $65.94 | $66.03 | 1.94M |
The latest Smart Investors Daily articles mentioning ALC.
Company
Market Activity
Research & News
ALC research
Company profile and research snapshot.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | BERENBERG | Buy | — |
| Aug 31, 2026 | BNP PARIBAS | Neutral | — |
| Aug 14, 2026 | EQUITA SIM | Buy | — |
| Aug 11, 2026 | NEEDHAM & COMPANY INC. | Buy | — |
| Jul 20, 2026 | DAY BY DAY | Sell | — |
No generated briefing is available yet.
Yahoo · Oct 7, 2026
MOUNTAIN VIEW, Calif., October 07, 2026--At AeraHUB 26, Aera Technology’s global decision intelligence event, enterprises share how they’re applying AI to the decisions that run the business.
Benzinga · Oct 7, 2026
Barclays analyst Christopher Pasquale initiates coverage on Alcon (NYSE:ALC) with a Equal-Weight rating and announces Price Target of $70.
Yahoo · Sep 28, 2026
TORONTO, September 28, 2026--Alcon, the global leader in eye care, announces the launch of Systane® PRO Preservative-Free (PF) in Canada.
Yahoo · Sep 27, 2026
Alcon has seen its share price grind lower in recent years, which naturally puts a spotlight on whether the current valuation still lines up with what the business earns. For anyone tracking the stock, the core question is whether the recent price level reflects a fair read of Alcon's earnings power. The share price has declined 26.8% over the past 5 years, which puts real pressure on the idea that the current market value is in step with the earnings the company produces. The business model...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALC.
